MISSION VIEJO, Calif., Aug. 22, 2018 (GLOBE NEWSWIRE) -- MYnd Analytics, Inc. (NASDAQ: MYND) (“MYnd” or the “Company”), a market leader in improving the delivery of mental health services and reducing costs through the combination of telemedicine and data analytics/artificial (augmented) intelligence, today announced that MYnd’s CEO, George Carpenter, presented at the 2018 Military Health System Research Symposium (MHSRS), held in Kissimmee, Florida from August 20th through 23rd.

The MHSRS is the Department of Defense’s premier scientific meeting. It provides a venue for presenting new scientific knowledge resulting from military-unique research and development. The MHSRS is the only military or civilian meeting that focuses specifically on the unique medical needs of the soldier. The MHSRS is an annual four-day educational symposium that draws approximately 2,300 attendees.

The presentation, co-authored by Mr. Carpenter and Dr. Mark Schiller, MYnd’s Medical Director, covered topics including the growing clinical evidence supporting the use of the Company’s Psychiatric EEG Evaluation Registry (PEER) report to improve patient outcomes, including reduced suicidal ideation, by providing physicians with objective, personalized data to assist in the selection of appropriate medications. Additional data presented included confirmative results from the recently published (Journal of the American Medical Association Psychiatry, June 2018) EMBARC trial (Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care), a multicenter trial that also involved researchers at Harvard Medical School and Massachusetts General Hospital, Columbia University, McLean Hospital, Stanford University, University of Pittsburgh, and the University of Michigan. EMBARC, funded by the National Institute of Mental Health, found that measuring electrical activity in the brain through the non-invasive EEG test can help predict a patient's response to an antidepressant.

Additionally, the Company presented findings that physicians using PEER guidance reduced theoccurrence of trial-and-error prescribing, resulting in both greater efficacy and improved patient adherence. Study results show a 4.7 to 1 net cost offset when tools such as PEER are applied to reduce trial and error treatment, which has recently been accepted for publication in the September 2018 issue of Population Health Management.

Finally, the Company presented data demonstrating that reduction in trial and error pharmacotherapy has been correlated with reduced suicidal ideation in three studies. These studies included a review of 435 patients, which found an 85% reduction in suicidal ideation for patients in the 722-day period following PEER-guided treatment, as well as results from the Walter Reed PEER Interactive Trial showing 75% higher suicidal ideation for subjects in the group that did not follow PEER recommended therapy.

George Carpenter, CEO of MYnd Analytics, commented, “We were honored to present at the 2018 MHSRS in front of some of the foremost military leaders, military healthcare providers, leading researchers and academic scientists, as well as potential partners. Sadly, too many of our military personnel suffer from mental health disorders including depression, post traumatic stress disorder, and suicidality. Fortunately, many of these conditions can be treated when physicians are armed with the appropriate tools. We have an obligation to our service men and women to provide them with the best possible care, and we believe the data we presented at this conference further reinforces the clinical value tools like PEER.”

About the Military Health System Research Symposium (MHSRS)

The MHSRS provides a collaborative setting for the exchange of information between military providers with deployment experience, research and academic scientists, international partners, and industry on research and related health care initiatives falling under the topic areas of Combat Casualty Care, Military Operational Medicine, Clinical and Rehabilitative Medicine, Medical Simulation and Information Sciences, and Military Infectious Disease.

About MYnd Analytics

MYnd Analytics, Inc. (www.myndanalytics.com) is a predictive analytics company that has developed a decision support tool to help physicians reduce trial and error treatment in mental health and provide more personalized care to patients. The Company’s Psychiatric EEG Evaluation Registry, or PEER Online, is a registry and reporting platform that allows medical professionals to exchange treatment outcome data for patients referenced to objective neurophysiology data obtained through a standard electroencephalogram (EEG). Based on the Company’s original physician-developed database, there are now more than 39,000 outcomes for over 11,000 unique patients in the PEER registry. The goal of PEER Online is to provide objective, personalized data to assist physicians in the selection of appropriate medications. To read more about the benefits of this patented technology for patients, physicians and payers, please visit: www.myndanalytics.com.

MYnd also operates its wholly owned subsidiarity Arcadian Telepsychiatry Services LLC which manages a suite of services including telepsychiatry, teletherapy, digital patient screening, curbside consultation, on-demand services, and scheduled encounters for all age groups. Arcadian utilizes patient engagement and re-engagement strategies so that care is effectively completed, helping to comfortably move inpatient care to outpatient, assisting patients in readjusting to their life routine, as well as reducing wait times for mental health treatment. Arcadian’s customer base includes major health plans, health systems, and community-based organizations.

Forward-looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements involve risks and uncertainties, such as statements regarding the MYnd’s, future revenues, future earnings, future number of patients or clients, our ability to drive growth, our ability to refocus our sales strategy, our ability to scale our business, benefits relating to our change in strategy, the ability of our offering to reach millions of Americans, developments relating to reimbursement and the health care market, regulatory developments, market developments, new products and growth strategies, our ability to successfully expand into various market channels, the ability of our products to successfully target objectivity and increased efficiency in the treatment of depression and other mental health and psychiatric illnesses, our ability to provide greater access to care, lower costs and help doctors reduce trial and error prescribing, our ability to target major payors or identify pilot programs, our ability to expand globally in areas where there is an opportunity to improve treatment in mental health, the effects of any of the foregoing on MYnd’s future results or operations or financial conditions, the ability of MYnd’s products to successfully target objectivity and increased efficiency in the treatment of depression and other mental health and psychiatric illnesses, as well as those risks and uncertainties set forth in MYnd's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.

Contact:

David Waldman / Natalya RudmanCrescendo Communications, LLCTel: +1 (212) 671-1020Email: mynd@crescendo-ir.com